Navigation Links
USC and second sight announce European clinical trial for Argus II retinal implant
Date:2/15/2008

Boston, MA, February 15, 2008 USC and Second Sight Medical Products Inc, leading developers of retinal prostheses for treating blindness, announced today that they have completed enrollment of the first phase of a U.S .FDA approved clinical study of the Argus II Retinal Prosthesis System. They also announced that enrollment at key European sites is underway as studies continue in Mexico.

We are pleased that Second Sight, along with our fantastic clinical partners, was able to fully enroll the US trial in a timely manner, said Robert Greenberg, MD, PhD, President and CEO of Second Sight, and a leader in the field of retinal prostheses for more than 15 years.

Although it is too early to comment on the clinical data, each device continues to function as expected, and all participants are using their systems at home daily.

The Argus II is the second generation of an electronic retinal implant designed for the treatment of blindness due to Retinitis Pigmentosa (RP), a group of inherited eye diseases that affect the retina. The Argus II implant consists of an array of 60 electrodes that are attached to the retina. These electrodes conduct information acquired from an external camera to the retina to provide a rudimentary form of sight to implanted subjects.

The development of this technology was largely supported by the National Eye Institute (NEI) of the National Institutes of Health (NIH), and the Department of Energys Office of Science (DOE) Artificial Retina Project, which is helping to advance the implants design and construction. The unique resources and expertise at DOE national laboratoriesparticularly in engineering, microfabrication, material science, and microelectronic technologiesare enabling the development of much smaller, higher resolution devices.

Ten subjects were recruited for the Phase I trial at four leading ophthalmic centers throughout the US, including the Doheny Eye Institute at the Univer
'/>"/>

Contact: Jon Weiner
jon.weiner@usc.edu
323-442-2830
University of Southern California
Source:Eurekalert

1

GOOD

Page: 1 2 3

Related biology technology :

1. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
2. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
3. Escalon(R) Reports Second Quarter Fiscal 2008 Results
4. Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
5. Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST
6. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
7. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
8. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008
9. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
10. Nutrition 21 to Report Second Quarter Fiscal 2008 Financial Results Monday, February 11, 2008
11. Neurobiological Technologies Sets Date for Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... May 20, 2013  Dr. Gerald Zon ... acid research, recently launched a new blog in conjunction ... ( zon.trilinkbiotech.com ), focuses on what,s trending in the ... industry thought leaders, discussions of research presented at conferences ... Dr. Zon (PhD Princeton University 1971) developed ...
(Date:5/20/2013)... With bed bugs' presence come problems in various terms. ... to be eliminated, one must make sure that the bed ... so to help bed bug sufferers get that done, it ... bugs without using harmful pesticides. In it, the company ... Bug Bully. , According to My Cleaning Products, contrary to ...
(Date:5/20/2013)... HILL, N.C. , May 20, 2013 /PRNewswire/ ... company focused on developing differentiated antibiotics to meet ... infections, today announced that it presented data at ... in Philadelphia demonstrating the ... levofloxacin in Cempra,s prior Phase 2 clinical trial ...
(Date:5/20/2013)... BOSTON , May 20, 2013 Rhythm ... clinical trial of RM-131, the company,s novel ghrelin agonist ... diabetic patients. The trial demonstrated that RM-131 significantly accelerates ... in type 1 diabetic patients with diabetic gastroparesis. The ... conference in Orlando and recently ...
Breaking Biology Technology:Dr. Gerald 'Jerry' Zon Launches New Blog for TriLink BioTechnologies 2New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products 2Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 2Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes 3
... Sept. 1 /PRNewswire-Asia-FirstCall/ -- China Kangtai Cactus,Biotech Inc. ... manufacturer and marketer of a variety of cactus-based ... successfully completed the trial,production of cactus-based cigarettes and ... in 2009: (i) low nicotine and (ii) zero ...
... ANNAPOLIS, Md., Sept. 1 PharmAthene, Inc. (NYSE Amex: ... against biological and chemical threats, announced today that management will ... 2009. The Company is scheduled to present on Thursday, ... Salon (5th Floor) at the New York Palace Hotel, New ...
... FORT LAUDERDALE, Fla., Sept. 1 OmniComm Systems, Inc. (OTC ... data capture (EDC) solutions for clinical trials, and ... announced today that three additional clinical research organizations ... the CRO Preferred Program. The partnership allows CROs in the ...
Cached Biology Technology:China Kangtai Cactus Biotech to Launch Patented Cactus-based Low Tar, Low or Zero Nicotine Cigarettes 2China Kangtai Cactus Biotech to Launch Patented Cactus-based Low Tar, Low or Zero Nicotine Cigarettes 3OmniComm Systems Inc. Expands Its Successful CRO Preferred Program(TM) By Signing On Three New CRO Partners 2OmniComm Systems Inc. Expands Its Successful CRO Preferred Program(TM) By Signing On Three New CRO Partners 3
(Date:5/20/2013)... articles posted online ahead of print 9 ... of geoscience subdisciplines, including minerals exploration, archaeology, planetary ... include Siberia; the Sumatran subduction margin; the Monte ... and the Southeastern U.S. Atlantic Margin. Brief highlights ... tectonics;, 2. The clear fingerprint of ice ages ...
(Date:5/18/2013)... today at Digestive Disease Week (DDW) explores new discoveries ... of coffee on autoimmune disease and palliative care for ... been associated with reduced risk of fibrosis, a new ... java each month also correlate with lower risk for ... Clinic, Rochester, MN, linked coffee consumption with reduced risk ...
(Date:5/17/2013)... of New Jersey, and City University of New York ... that effectively clears organisms to be viewed under ... hydrate, which is one of the few high-quality clearing ... the Drug Enforcement Administration (DEA) due to its use ... are vital for viewing organisms under a microscope. Without ...
Breaking Biology News(10 mins):New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 2New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 3New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 4New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 5New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 6New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 7New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 8New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 9New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 10New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 11Coffee consumption associated with reduced risk of autoimmune liver disease 2New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3
... more to fighting infection than just clearing the body of ... the host,s tissue caused, very frequently, by toxins produced by ... clears those pathogens. Indeed, it is the damage inflicted to ... the lethal outcome of some infectious diseases. , The ...
... the current issue of Science , researchers at Michigan ... light on how easy it can be for diseases to ... time how the virus called "Lambda" evolved to find a ... four mutations to accomplish. This virus infects bacteria, in particular ...
... -- (Jan. 26, 2012) -- Like a magician employing sleight ... player in diabetes, cancer and aging -- draws the eye ... subtle, more crucial action takes place somewhere else. Using ... Rice University and the University of California, San Diego (UCSD) ...
Cached Biology News:European Research Council supports search for regulators of tissue damage 2MSU researchers show how new viruses evolve, and in some cases, become deadly 2Rice, UCSD scientists probe form, function of mysterious protein 2Rice, UCSD scientists probe form, function of mysterious protein 3
Rabbit polyclonal to Myosin VIIa (rating: *****) ( Abpromise for all tested applications). entrezGeneID: 4647 SwissProtID: Q13402...
Rabbit polyclonal to GPCR G2A ( Abpromise for all tested applications). entrezGeneID: 29933 SwissProtID: Q9UNW8...
6-keto Prostaglandin F1α EIA Antiserum 6-keto-PGF1alpha EIAs prostaglandins antisera enzyme immunoassays reagents 6-keto-PGF1.alpha....
...
Biology Products: